Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Drug Delivery

Background:

• Carbamazepine is essential for epilepsy and trigeminal neuralgia but faces challenges like poor bioavailability and toxicity.
• Current oral administration requires dose adjustments and carries risks of long-term side effects.

Purpose of the Study:

• To develop and evaluate novel beeswax-containing nanostructured lipid carrier (NLC) formulations for improved carbamazepine oral delivery.
• To overcome the limitations of conventional carbamazepine administration, including bioavailability and toxicity.

Main Methods:

• NLC formulations were prepared using high shear homogenization and sonication.
• In vitro and in vivo studies assessed particle size, surface charge, encapsulation efficiency, drug release, pharmacokinetics, anticonvulsant activity, and toxicity.
• Fourier-transform infrared spectroscopy and thermal analysis were used to study drug-NLC interactions.

Main Results:

• Successfully produced NLCs with nanometric particle size and high encapsulation efficiencies (93.1–95.7%).
• In vitro release showed a biphasic pattern, with faster release at higher beeswax concentrations.
• Pharmacokinetic studies revealed significantly improved bioavailability (2.27-fold vs. suspension, 1.83-fold vs. Tegretol™) without plasma fluctuations.
• Enhanced anticonvulsant activity and undetectable liver/testicular toxicity were observed.

Conclusions:

• Beeswax-based NLCs offer a promising system for safe and effective oral delivery of carbamazepine.
• This NLC formulation overcomes key limitations of conventional carbamazepine, improving therapeutic outcomes and patient safety.